Clinical Trial Spotlight on CheckMate 274 Trial: New Era in Adjuvant Muscle Invasive Urothelial Carcinoma (MIUC)
SIU Academy®. Faculty / Presenter(s) . 05/21/21; 321264 Topic: Research
 Faculty / Presenter(s)
Faculty / Presenter(s)
About this activity
The CheckMate 274 trial is foundational to the management of MIUC because it demonstrated that adjuvant immunotherapy with nivolumab could extend the time to disease recurrence among high-risk patients, regardless of whether they received neoadjuvant treatment with cisplatin-based therapy.

This Expert Highlights session summarizes the key findings of CheckMate 274 and what they mean for the management of MIUC and provides guidance to the urological community on how these findings can best be incorporated into their practices.

Peter Black, MD, FACS, FRCSC
Khosrowshahi Family Chair
Professor, Vancouver Prostate Centre, Dept. of Urologic Sciences, University of British Columbia
Vancouver, Canada
Editor-in-Chief, SIU Journal

Matthew Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Genitourinary Medical Oncology
Associate Director, Translational Research
Tisch Cancer Institute
New York, United States

This educational activity is supported by SIU Corporate Sponsor Bristol Myers Squibb​.


By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies